Our CEO Poul Sørensen shared our latest progress this morning at RNA Leaders in Vienna
#RNATherapeutics #Pseudoexon #Parkinsons #Huntingtons #RNAleaders

A deep intronic variant in PHKG2 caused #pseudoexon inclusion and GSD IX γ2 in two siblings, highlighting a pathway to detect and reverse non-coding splicing defects using RNA-seq and #antisensetherapy. bit.ly/4pMlNdS #GIMO #GlycogenStorageDisease #NonCodingVariants

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research | Inverna Therapeutics Inverna Therapeutics is delighted to announce the formation of our new Scientific Advisory Board (SAB)🚀 We welcome world-renowned leaders in RNA therapeutics and neurodegenerative research to advance...

Exciting news from Inverna ! 🎉

www.linkedin.com/posts/invern...
#RNATherapeutics #Pseudoexon #ASO #Innovation

#invernatherapeutics #mjff #grant #parkinsonsdisease #lrrk2 #biotech #startup #neuroscience #innovation | Inverna Therapeutics 🎉 Exciting news from Inverna Therapeutics! 🚀 We’re honored to announce that Inverna has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) as part of the LRRK2 Inv...

Big news today! 🎉
#MJFF #RNAtherapeutics #Parkinsondisease #RNAsplicingmodulation #Pseudoexon #Innovation

#bioeuropespring #rnasplicingmodulation #pseudoexons | Mads Aaboe Jensen, MSc, PhD Poul Sørensen, CEO, is presenting Inverna’s platform for RNA splicing modulation at BIO-Europe Spring 2025 in Milan. #BioEuropeSpring #RNASplicingModulation…

Great pitching Inverna and our novel RNA splicing modulation platform at the BIO Europe Spring Startup Spotlight competition ! www.linkedin.com/posts/mads-a...
#RNAtherapeutics #Splicingmodulation #pseudoexon #innovation @invernatx.com